⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 20, 2014Breast Cancer ResearchOpen Access

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes

Patrick Maisonneuve Davide Disalvatore Nicole Rotmensz Giuseppe Curigliano Marco Colleoni Silvia Dellapasqua Giancarlo Pruneri Mauro G. Mastropasqua Alberto Luini Fabio Bassi Gianmatteo Pagani Giuseppe Viale Aron Goldhirsch

View Full Paper

Ask AI

Bookmark

Share

Abstract

The updated pathological definition of intrinsic molecular subtypes may maximize the number of patients classified as having the luminal A-like intrinsic subtype of breast cancer and for whom the use of cytotoxic drugs could mostly be avoided.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Maisonneuve et al. (2014) studied this question.

synapsesocial.com/papers/69d8125266a29169b4bee228 https://doi.org/10.1186/bcr3679

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Original Research · 2013 · 3,749 citations
2Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast CancerPrognostic Study · 2012 · 587 citations
3Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Original Research · 2011 · 3,837 citations
4Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerPrognostic Study · 2009 · 2,252 citations
5pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upOriginal Research · 1991 · 6,179 citations

More related papers

A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer2010
PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers2012
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures2008

More from Breast Cancer Research

Prognostic value of tumor maximum standardized uptake value on positron emission tomography/computed tomography for 10-year survival in early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: a retrospective studyMon,
Spatial localization of RNAs within the breast tumor microenvironment may affect progression and recurrence of DCISFri,